Your browser doesn't support javascript.
loading
Reaserch Advances in the Treatment of Primary Immune Thrombocytopenia--Review / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 983-987, 2021.
Article in Chinese | WPRIM | ID: wpr-880179
ABSTRACT
Primary immune thrombocytopenia (ITP) is a blood system disease mediated by autoimmune mechanism. Currently, the goal of treatment for primary ITP is to keep patients' peripheral platelet count at a safe level to prevent severe bleeding. Recently, avatrombopag and fostamatinib have been approved by the FDA for the treatment of primary ITP in adults, while new drugs such as rozanolixizumab, efgartigimod, PRTX-100, decitabine and atorvastatin have shown efficacy in early clinical trials. This review summarizes the current accepted therapies for the clinical treatment of primary ITP in adults, and briefly discuss the progress of new therapies.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Platelet Count / Splenectomy / Purpura, Thrombocytopenic, Idiopathic / Hemorrhage Limits: Adult / Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Platelet Count / Splenectomy / Purpura, Thrombocytopenic, Idiopathic / Hemorrhage Limits: Adult / Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article